Avant Technologies and Austrianova Advancing ?-Klotho Cell Therapy as Mayo Clinic Study Links Low ?-Klotho Levels to Poor Cardiovascular Survival

Stock Information for Avant Technologies Inc

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Avant Technologies Inc

Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions
THE CRITICAL LIST: 5 Stocks Anchoring the New Economy
THE EFFICIENCY PARADOX: 5 Market Anomalies Trading Below Reality
Avant Technologies and Austrianova Secure Exclusive License for Klotho Producing Cell Line to Advance Anti-Aging Therapies
Avant Technologies Signs Joint Venture to Advance Cell-Based Diabetes Treatment
Avant Technologies and Austrianova Launch Klothonova, Begin Developing Age Related Cellular Therapies Using 'Longevity Protein' Klotho
Healthcare Innovation Accelerates as Four Converging Forces Drive Early Intervention Focus
Avant Technologies, Inc. Bolsters Strategic Vision with Targeted Biotech Partnerships for Innovative Cell-Based Therapies

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.